Biomarkers

Share:
ResearchersAgainstAlzheimer's would like to thank Roche Diagnostics for their support of this project.
Return to the full list of Biomarkers

18F-AV-1451 (F 18 T807)

Method of Measurement (Pre-analytical Tools)
Imaging
Biomarker Measured
Tau
Use
Prognostic
Susceptibility/risk
Stage of Development
Clinical trials
Active vs Completed Trials
Active
Aim/Results

Obtain preliminary data that will support the possibility of detecting cognitive decline in its earliest stages, before the occurrence of dementia. This project will also collect quantitative pilot data that will allow the characterization of uptake and binding of 18F-AV-1451 (also known as F 18 T807), a novel tau imaging compound, in individuals with Progressive Posterior Cortical Dysfunction (PPCD) and logopenic variant primary progressive aphasia (lvPPA). (Protocol E)

Target Population/ Population Being Studied

Patients with a clinical diagnosis of PPCD (Protocol E)

Length of Current Trial
5 years (Protocol E)
Number of Trial Participants

25 (Protocol E)

Estimated Trial Completion
September 2020 (Protocol E)
What is Required from Patients

injection of radioactive tracers, mild discomfort, in clinic visit

What is Required from the Health System

PET technician, PET scanner, dyes

Sponsor

Washington University School of Medicine

  1. “Evaluating the Relationship Between Tau PET Imaging and CSF Biomarkers of AD (Alzheimer Disease) in Humans (ADRC proj 1).” ClinicalTrials.gov. Accessed October 9, 2020. https://clinicaltrials.gov/ct2/show/NCT03287765?term=biomarker&recrs=abdf&cond=Alzheimer+Disease&rank=9 

  2. “F 18 T807 Tau PET Imaging in Dominantly Inherited Alzheimer's Network (DIAN Project) (AV ADAD).” ClinicalTrials.gov. Accessed October 9, 2019. https://clinicaltrials.gov/ct2/show/NCT02414178?term=18F-AV-1451&recrs=adf&cond=alzheimers&rank=5

  3. “F 18 T807 Tau PET Imaging of Alzheimer's Disease (T807IND).” ClinicalTrials.gov. Accessed October 9, 2020. https://clinicaltrials.gov/ct2/show/NCT02414347?term=biomarker&recrs=abdf&cond=Alzheimer+Disease&draw=9&rank=79

  4. “F 18 T807 Tau PET Imaging of Progressive Posterior Cortical Dysfunction (IND 123119, Protocol E) (Protocol E).” ClinicalTrials.gov. Accessed October 9, 2019. https://clinicaltrials.gov/ct2/show/NCT02414282?term=biomarker&recrs=abdf&cond=Alzheimer+Disease&draw=10&rank=88

  5. “Longitudinal Early-onset Alzheimer's Disease Study Protocol (LEADS).”ClinicalTrials.gov. Accessed October 9, 2019. https://clinicaltrials.gov/ct2/show/NCT03507257?term=18F-AV-1451&recrs=adf&cond=alzheimers&rank=3

  6. “Tau PET Imaging in Atypical Dementias.” ClinicalTrials.gov. Accessed October 9, 2019. https://clinicaltrials.gov/ct2/show/NCT03283449?term=18F-AV-1451&recrs=adf&cond=alzheimers&rank=10